The Evidence on Ozempic to Treat Addiction
The New Yorker
February 20, 2026
AI-Generated Deep Dive Summary
The New Yorker Radio Hour explores the groundbreaking potential of GLP-1 drugs like Ozempic to treat addiction, marking a shift from their traditional use in managing diabetes and obesity. Dhruv Khullar, a physician and medical correspondent, highlights emerging evidence suggesting these medications may significantly reduce cravings for substances like alcohol and cocaine. Anecdotal reports from patients indicate improved control over addictive behaviors, sparking interest among researchers who are now testing GLP-1 drugs as potential treatments for a range of addictions, including gambling and excessive online shopping.
GLP-1 drugs, which regulate appetite and metabolism, have already gained widespread use: one in eight Americans currently takes them. While initially prescribed for weight management and blood sugar control, users have reported unexpected benefits, such as reduced alcohol consumption and decreased drug use. Khullar’s reporting emphasizes the growing body of evidence supporting these observations, with scientists exploring how GLP-1 drugs influence brain chemistry to curb addictive tendencies. Early trials show promising results, though researchers stress that more studies are needed to fully understand their effectiveness and long-term impacts.
The implications for addiction treatment are profound. If successful, GLP-1 drugs could offer a biologically based alternative to traditional therapies
Verticals
culturenews
Originally published on The New Yorker on 2/20/2026